| | 
 |
| IMUNAID
| | AIDS
- ANTI RETROVIRAL COMBINATION DRUG |
| ANTI
VIRALS - 2 NRTI + 1 NNRTI COMBINATION | |
| | | | | | | |
| Composition
/ Chemical Make Up |
| IMUNAID-
30 | |
| | Each
uncoated tablet contains: | | | Stavudine | 30
mg | | | Lamivudine | 150mg
| | | Nevirapine | 200
mg | | | Color:
Lake Quinoline Yellow WS | |
| IMUNAID-
40 | |
| | Each
uncoated tablet contains: | | | Stavudine | 40
mg | | | Lamivudine | 150mg
| | | Nevirapine | 200
mg | | | Color:
Lake Quinoline Yellow FCF | |
| | |
| Description |
| | Imunaid
is a combination of 3 drugs commonly used in the management of Human Immunodeficiency
Virus (HIV-1) infection. Both stavudine and lamivudine belong to the nucleoside
analogue class of antiretroviral drugs. Both drugs act by terminating the growth
of the DNA chain and inhibiting the reverse transcriptase of HIV. Nevirapine is
a non-necleoside reverse transcriptase inhibitor. It acts by directly inhibiting
reverse transcriptase. Studies using the combination of stavudine + lamuvidine
+ nevirapine have demonstrated its efficacy in patients with HIV infection. In
the study presentby by Kaspar et al at the 5th conference on Retroviruses and
Opportunistic Infections, Chicago 1998, 87% of the patients had undetectable viral
loads at 33-44 weeks. In the study presented by Russell et al at the 7th Conference
on Clinical Aspects and Treatment of HIV Infection, Lisbon 1999, CD4 counts increased
by 195 cells/mm3 and 230 cells/mm3 in patients with low (<80, 000 copies/ml) and
high viral loads (>80, 000 copies/ml) respectively at the end of the 1st year.
72% of patients with low viral loads and 80% of patients with high viral loads
had undetectable viral loads at the end of 1 year.
Eact tablet of Imunaid
contains half of the commonly prescribed daily doses of stavudine, lamivudine
and nevirapine. All three drugs are to be administered twice daily, permitting
a fixed dose combination to be formulated. With the availability of this combination
formulation, patients may be better able to adhere to triple drug regimens, thereby
enhancing compliance. | |
|
| | |
Indications |
| | Imunaid
is indicated for the treatment of HIV-1 infection in adults, once patients have
been stabilized on the maintainence regimen of nevirapine 200 mg bd, and have
demonstrated adequate tolerability to nevirapine. | |
| | |
Presentation |
| |
Imunaid - 30
Container of 30/ 60 tablets
Imunaid - 40 Container of 30/ 60
tablets | |
| | |
Dosage & Administration |
| | Adults
:
Imunaid - 30
1 tablet twice a day for patients weighing
< 60 kg
Imunaid - 40
1 tablet twice a day for patients weighing
³ 60 kg
Imunaid should not be administered to patients who have just
initiated therapy with nevirapine. This is because an intial lead-in dosing of
200 mg nevirapine once daily for 2 weeks is recommended. Following this lead-in
dose, a dose escalation (maintainence dose) to 200 mg nevirapine bd may be carried
out in the absence of any hypersensitivity reactions ( e.g. rash, liver function
test abnormalities; see Warnings and Precautions). | |
| | |
Monitoring of
Patients | | |
Clinical chemistry
tests, which include liver function tests, should be performed prior to initiating
lead-in nevirapine therapy and at appropriate intervals during therapy (see Warnings
and Precautions). | |
| | | | Generic
pharmaceutical formulations and medicines, herbal medicines, nutraceuticals &
supplements. We also develop products based on individual buyer requirements for
global import export markets. Leaders in healthcare marketing in India.
Imunaid
is a registered trade mark of Ezee Soulnature Healthcare P L. India
| | NEWS
FLASH:
LOOKING FOR EXLUSIVE DISTRIBUTORS IN EU, USA & CANADA FOR OUR 80 HERBAL
PRODUCTS RANGE - FOOD SUPPLEMENTS & PERSONAL CARE
| |
